World Allergy Organization Journal (Sep 2024)
Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study
- Hyo-In Rhyou, MD, PhD,
- Hyun-Kyoung Kim, MPH,
- Woo-Jung Song, MD, PhD,
- Sang Min Lee, MD, PhD,
- Sang-Ha Kim, MD, PhD,
- Jae-Woo Kwon, MD, PhD,
- Han-Ki Park, MD, PhD,
- Hye-Kyung Park, MD, PhD,
- Sang Hoon Kim, MD, PhD,
- Jeong-Hee Choi, MD, PhD,
- Sujeong Kim, MD, PhD,
- So-Young Park, MD, PhD,
- Sae-Hoon Kim, MD, PhD,
- Ji-Yong Moon, MD, PhD,
- Jae-Woo Jung, MD, PhD,
- Young-Joo Cho, MD, PhD,
- Chan Sun Park, MD, PhD,
- Byung Keun Kim, MD, PhD,
- Joo-Hee Kim, MD, PhD,
- Min-Suk Yang, MD, PhD,
- Min-Hye Kim, MD, PhD,
- Young-Hee Nam, MD, PhD,
- Taehoon Lee, MD, PhD,
- Byung-Jae Lee, MD, PhD,
- Pankaj Bhavsar, PhD,
- Ian M. Adcock, PhD,
- Kian Fan Chung, MD, DSc,
- Tae-Bum Kim, MD, PhD
Affiliations
- Hyo-In Rhyou, MD, PhD
- Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea
- Hyun-Kyoung Kim, MPH
- Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- Woo-Jung Song, MD, PhD
- Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- Sang Min Lee, MD, PhD
- Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea
- Sang-Ha Kim, MD, PhD
- Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea
- Jae-Woo Kwon, MD, PhD
- Department of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, South Korea
- Han-Ki Park, MD, PhD
- Department of Allergy and Clinical Immunology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea
- Hye-Kyung Park, MD, PhD
- Department of Internal Medicine, Pusan National University Hospital, Pusan National University College of Medicine, Busan, South Korea
- Sang Hoon Kim, MD, PhD
- Department of Internal Medicine, Nowon Eulji Hospital, Eulji University School of Medicine, Seoul, South Korea
- Jeong-Hee Choi, MD, PhD
- Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea
- Sujeong Kim, MD, PhD
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea
- So-Young Park, MD, PhD
- Division of Pulmonary, Allergy and Critical Care medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea
- Sae-Hoon Kim, MD, PhD
- Department of Internal Medicine, Division of Allergy and Clinical Immunology, Seoul National University Bundang Hospital, Seongnam, South Korea
- Ji-Yong Moon, MD, PhD
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea
- Jae-Woo Jung, MD, PhD
- Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea
- Young-Joo Cho, MD, PhD
- Department of Allergy and Clinical Immunology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, South Korea
- Chan Sun Park, MD, PhD
- Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea
- Byung Keun Kim, MD, PhD
- Department of Internal Medicine, Korea University Medical Center Anam Hospital, Seoul, South Korea
- Joo-Hee Kim, MD, PhD
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea
- Min-Suk Yang, MD, PhD
- Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea
- Min-Hye Kim, MD, PhD
- Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, South Korea
- Young-Hee Nam, MD, PhD
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea
- Taehoon Lee, MD, PhD
- Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
- Byung-Jae Lee, MD, PhD
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Pankaj Bhavsar, PhD
- National Heart and Lung Institute, Imperial College London, United Kingdom
- Ian M. Adcock, PhD
- National Heart and Lung Institute, Imperial College London, United Kingdom
- Kian Fan Chung, MD, DSc
- National Heart and Lung Institute, Imperial College London, United Kingdom
- Tae-Bum Kim, MD, PhD
- Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Corresponding author. Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olymphic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.
- Journal volume & issue
-
Vol. 17,
no. 9
p. 100957
Abstract
Background: Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, studies comparing different biologics are lacking. We evaluated the QoL in patients with severe asthma comprehensively and compare the efficacy of different T2-directed biologics using QoL questionnaires. Methods: We compared the QoL between severe and mild-to-moderate asthma and between severe asthma with and without biologics treatment. Data of mild-to-moderate were extracted from the Cohort for Reality and Evolution of Adult Asthma in Korea, and data of severe asthma were collected from the Precision Medicine Intervention in Severe Asthma. We included 183 patients with severe asthma treated with T2 biologics or conventional therapy between April 2020 and May 2021 and assessed QoL of them using the Questionnaire for Adult Korean Asthmatics (QLQAKA), Severe Asthma Questionnaire (SAQ), and EuroQoL-5Dimensions (EQ-5D) at baseline and 6 months. Results: The EQ-5D index (0.803) of severe asthma was lower than that of other chronic diseases representing a worse QoL. The scores for all questions of QLQAKA, except “cough,” were lower (less control) in the severe asthma group than in the mild-to-moderate asthma group at baseline and 6 months (P 0.05). Conclusion: QoL was worse in severe asthma than in mild-to-moderate asthma and other chronic diseases. T2 biologics equally improved QoL in patients with severe asthma.
